What is a stock summary page? Click here for an overview.
Business Description
TherapeuticsMD Inc
NAICS : 325412
SIC : 2834
ISIN : US88338N1072
Compare
Compare
Traded in other countries / regions
TXMD.USA29TA.Germany Index Membership
Russell 2000 IPO Date
2007-05-09Description
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.68 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -1.92 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -33.26 | |||||
| Beneish M-Score | 36.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -78 | |||||
| 3-Year EBITDA Growth Rate | 70.3 | |||||
| 3-Year EPS without NRI Growth Rate | 71.9 | |||||
| 3-Year FCF Growth Rate | 57.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.11 | |||||
| 9-Day RSI | 58.75 | |||||
| 14-Day RSI | 55.35 | |||||
| 3-1 Month Momentum % | 8.14 | |||||
| 6-1 Month Momentum % | -43.29 | |||||
| 12-1 Month Momentum % | -59.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.03 | |||||
| Quick Ratio | 2.03 | |||||
| Cash Ratio | 0.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.4 | |||||
| Shareholder Yield % | 6.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -300.19 | |||||
| Net Margin % | -207.77 | |||||
| FCF Margin % | 66.44 | |||||
| ROE % | -11.78 | |||||
| ROA % | -7.69 | |||||
| ROIC % | -13.03 | |||||
| 3-Year ROIIC % | -809.61 | |||||
| ROC (Joel Greenblatt) % | -73.25 | |||||
| ROCE % | -13.92 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 5.81 | |||||
| PS Ratio | 7.34 | |||||
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.51 | |||||
| EV-to-EBIT | -3.84 | |||||
| EV-to-EBITDA | -4.5 | |||||
| EV-to-Revenue | 7.62 | |||||
| EV-to-Forward-Revenue | 0.95 | |||||
| EV-to-FCF | -3.52 | |||||
| Earnings Yield (Greenblatt) % | -26.04 | |||||
| FCF Yield % | 10.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TXMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TherapeuticsMD Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.761 | ||
| EPS (TTM) ($) | -0.18 | ||
| Beta | 0.72 | ||
| 3-Year Sharpe Ratio | -0.66 | ||
| 3-Year Sortino Ratio | -0.88 | ||
| Volatility % | 64.66 | ||
| 14-Day RSI | 55.35 | ||
| 14-Day ATR ($) | 0.095551 | ||
| 20-Day SMA ($) | 0.85895 | ||
| 12-1 Month Momentum % | -59.91 | ||
| 52-Week Range ($) | 0.7 - 2.44 | ||
| Shares Outstanding (Mil) | 11.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TherapeuticsMD Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TherapeuticsMD Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TherapeuticsMD Inc Frequently Asked Questions
What is TherapeuticsMD Inc(TXMD)'s stock price today?
The current price of TXMD is $1.00. The 52 week high of TXMD is $2.44 and 52 week low is $0.70.
When is next earnings date of TherapeuticsMD Inc(TXMD)?
The next earnings date of TherapeuticsMD Inc(TXMD) is 2025-05-09 Est..
Does TherapeuticsMD Inc(TXMD) pay dividends? If so, how much?
TherapeuticsMD Inc(TXMD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers